Extracellular chromatin fragments as biomarkers for cancer screening
Seminars in Cancer Biology · 2026
DOI: 10.1016/j.semcancer.2026.102617 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2026. Verfasst von Manlio Vinciguerra und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Stem Cell Biology, Research Institute, Medical University Varna, Varna, Bulgaria; LUM University, Casamassima (BA), Italy…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasms, Chromatin, Early Detection of Cancer. Die Arbeit nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BNSF.
Abstract (Originalsprache)
Extracellular chromatin fragments, including cell-free DNA (cfDNA) and histones, have emerged as promising non-invasive biomarkers for cancer screening and monitoring. While aberrant DNA methylation patterns in cfDNA are already established hallmarks of cancer and are increasingly used in liquid biopsy assays, circulating histones and nucleosomes reflect complementary aspects of tumor-associated epigenetic dysregulation and chromatin remodeling. This review integrates current knowledge on intracellular and extracellular histones in cancer, highlighting their release via necrosis, apoptosis, or neutrophil extracellular traps (NETs), and their dual roles as damage-associated molecular patterns and modulators of the tumor microenvironment. We discuss the intricate mechanistic links between DNA methylation and histone modifications, histone variants, and post-translational modifications, including the bidirectional crosstalk mediated by enzymes such as DNMTs, UHRF1, and PAD4. Special emphasis is placed on NETosis and its epigenetic regulation, which further connects histone citrullination with DNA methylation machinery and tumor progression. We evaluate the clinical potential of combining cfDNA methylation profiling with circulating histone levels, histone variants, and nucleosome-associated post-translational modifications. Evidence from multiple cancer types demonstrates that multimodal epigenetic approaches, incorporating fragmentomics, histone marks, and methylation signatures, significantly improve diagnostic accuracy, tissue-of-origin identification, and early detection compared to single-modality or conventional protein biomarkers in several cancer types. Fragmentomics, reflecting nucleosome positioning and chromatin accessibility, adds a functional layer to methylation-based assays. Collectively, extracellular chromatin components offer a rich, biologically interconnected source of information. Their integrated analysis holds substantial promise for advancing precision oncology through improved screening, prognosis, treatment monitoring, and development of safer epigenetic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Stem Cell Biology, Research Institute, Medical University Varna, Varna, Bulgaria; LUM University, Casamassima (BA), Italy. Electronic address: manlio.vinciguerra@mu-varna.bg.
- Department of Translational Stem Cell Biology, Research Institute, Medical University Varna, Varna, Bulgaria; Department of Medical Genetics, Medical University Varna, Varna, Bulgaria.
Förderung
- BNSF
Zitieren
APA
Vinciguerra, M., & K Tsoneva, D. (2026). Extracellular chromatin fragments as biomarkers for cancer screening. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2026.102617
Vancouver
Vinciguerra M, K Tsoneva D. Extracellular chromatin fragments as biomarkers for cancer screening. Seminars in Cancer Biology. 2026. doi:10.1016/j.semcancer.2026.102617
BibTeX
@article{Vinciguerra2026,
author = {Vinciguerra, Manlio and K Tsoneva, Desislava},
title = {Extracellular chromatin fragments as biomarkers for cancer screening},
journal = {Seminars in Cancer Biology},
year = {2026},
doi = {10.1016/j.semcancer.2026.102617}
}
EUVIMED